Global Myotonic Dystrophy Therapeutics Supply, Demand and Key Producers, 2024-2030

Description

The global Myotonic Dystrophy Therapeutics market size is expected to reach $ 73 million by 2030, rising at a market growth of 6.1% CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

This report studies the global Myotonic Dystrophy Therapeutics production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Myotonic Dystrophy Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Myotonic Dystrophy Therapeutics that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Myotonic Dystrophy Therapeutics total production and demand, 2019-2030, (K Units)
Global Myotonic Dystrophy Therapeutics total production value, 2019-2030, (USD Million)
Global Myotonic Dystrophy Therapeutics production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Myotonic Dystrophy Therapeutics consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Myotonic Dystrophy Therapeutics domestic production, consumption, key domestic manufacturers and share
Global Myotonic Dystrophy Therapeutics production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Myotonic Dystrophy Therapeutics production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Myotonic Dystrophy Therapeutics production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).

This reports profiles key players in the global Myotonic Dystrophy Therapeutics market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lupin, Teva, ANI Pharmaceuticals, Viatris, Novartis, Sun Pharma and Mallinckrodt, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Myotonic Dystrophy Therapeutics market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Myotonic Dystrophy Therapeutics Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Myotonic Dystrophy Therapeutics Market, Segmentation by Type
    Sodium Channel Blocker
    Tricyclic Antidepressant
    Other

Global Myotonic Dystrophy Therapeutics Market, Segmentation by Application
    Hospital Pharmacy
    Retail Pharmacy
    Other

Companies Profiled:
    Lupin
    Teva
    ANI Pharmaceuticals
    Viatris
    Novartis
    Sun Pharma
    Mallinckrodt

Key Questions Answered
1. How big is the global Myotonic Dystrophy Therapeutics market?
2. What is the demand of the global Myotonic Dystrophy Therapeutics market?
3. What is the year over year growth of the global Myotonic Dystrophy Therapeutics market?
4. What is the production and production value of the global Myotonic Dystrophy Therapeutics market?
5. Who are the key producers in the global Myotonic Dystrophy Therapeutics market?

Table of Contents

1 Supply Summary
    1.1 Myotonic Dystrophy Therapeutics Introduction
    1.2 World Myotonic Dystrophy Therapeutics Supply & Forecast
        1.2.1 World Myotonic Dystrophy Therapeutics Production Value (2019 & 2023 & 2030)
        1.2.2 World Myotonic Dystrophy Therapeutics Production (2019-2030)
        1.2.3 World Myotonic Dystrophy Therapeutics Pricing Trends (2019-2030)
    1.3 World Myotonic Dystrophy Therapeutics Production by Region (Based on Production Site)
        1.3.1 World Myotonic Dystrophy Therapeutics Production Value by Region (2019-2030)
        1.3.2 World Myotonic Dystrophy Therapeutics Production by Region (2019-2030)
        1.3.3 World Myotonic Dystrophy Therapeutics Average Price by Region (2019-2030)
        1.3.4 North America Myotonic Dystrophy Therapeutics Production (2019-2030)
        1.3.5 Europe Myotonic Dystrophy Therapeutics Production (2019-2030)
        1.3.6 China Myotonic Dystrophy Therapeutics Production (2019-2030)
        1.3.7 Japan Myotonic Dystrophy Therapeutics Production (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Myotonic Dystrophy Therapeutics Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Myotonic Dystrophy Therapeutics Major Market Trends

2 Demand Summary
    2.1 World Myotonic Dystrophy Therapeutics Demand (2019-2030)
    2.2 World Myotonic Dystrophy Therapeutics Consumption by Region
        2.2.1 World Myotonic Dystrophy Therapeutics Consumption by Region (2019-2024)
        2.2.2 World Myotonic Dystrophy Therapeutics Consumption Forecast by Region (2025-2030)
    2.3 United States Myotonic Dystrophy Therapeutics Consumption (2019-2030)
    2.4 China Myotonic Dystrophy Therapeutics Consumption (2019-2030)
    2.5 Europe Myotonic Dystrophy Therapeutics Consumption (2019-2030)
    2.6 Japan Myotonic Dystrophy Therapeutics Consumption (2019-2030)
    2.7 South Korea Myotonic Dystrophy Therapeutics Consumption (2019-2030)
    2.8 ASEAN Myotonic Dystrophy Therapeutics Consumption (2019-2030)
    2.9 India Myotonic Dystrophy Therapeutics Consumption (2019-2030)

3 World Myotonic Dystrophy Therapeutics Manufacturers Competitive Analysis
    3.1 World Myotonic Dystrophy Therapeutics Production Value by Manufacturer (2019-2024)
    3.2 World Myotonic Dystrophy Therapeutics Production by Manufacturer (2019-2024)
    3.3 World Myotonic Dystrophy Therapeutics Average Price by Manufacturer (2019-2024)
    3.4 Myotonic Dystrophy Therapeutics Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Myotonic Dystrophy Therapeutics Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Myotonic Dystrophy Therapeutics in 2023
        3.5.3 Global Concentration Ratios (CR8) for Myotonic Dystrophy Therapeutics in 2023
    3.6 Myotonic Dystrophy Therapeutics Market: Overall Company Footprint Analysis
        3.6.1 Myotonic Dystrophy Therapeutics Market: Region Footprint
        3.6.2 Myotonic Dystrophy Therapeutics Market: Company Product Type Footprint
        3.6.3 Myotonic Dystrophy Therapeutics Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Myotonic Dystrophy Therapeutics Production Value Comparison
        4.1.1 United States VS China: Myotonic Dystrophy Therapeutics Production Value Comparison (2019 & 2023 & 2030)
        4.1.2 United States VS China: Myotonic Dystrophy Therapeutics Production Value Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States VS China: Myotonic Dystrophy Therapeutics Production Comparison
        4.2.1 United States VS China: Myotonic Dystrophy Therapeutics Production Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Myotonic Dystrophy Therapeutics Production Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States VS China: Myotonic Dystrophy Therapeutics Consumption Comparison
        4.3.1 United States VS China: Myotonic Dystrophy Therapeutics Consumption Comparison (2019 & 2023 & 2030)
        4.3.2 United States VS China: Myotonic Dystrophy Therapeutics Consumption Market Share Comparison (2019 & 2023 & 2030)
    4.4 United States Based Myotonic Dystrophy Therapeutics Manufacturers and Market Share, 2019-2024
        4.4.1 United States Based Myotonic Dystrophy Therapeutics Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Myotonic Dystrophy Therapeutics Production Value (2019-2024)
        4.4.3 United States Based Manufacturers Myotonic Dystrophy Therapeutics Production (2019-2024)
    4.5 China Based Myotonic Dystrophy Therapeutics Manufacturers and Market Share
        4.5.1 China Based Myotonic Dystrophy Therapeutics Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Myotonic Dystrophy Therapeutics Production Value (2019-2024)
        4.5.3 China Based Manufacturers Myotonic Dystrophy Therapeutics Production (2019-2024)
    4.6 Rest of World Based Myotonic Dystrophy Therapeutics Manufacturers and Market Share, 2019-2024
        4.6.1 Rest of World Based Myotonic Dystrophy Therapeutics Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Myotonic Dystrophy Therapeutics Production Value (2019-2024)
        4.6.3 Rest of World Based Manufacturers Myotonic Dystrophy Therapeutics Production (2019-2024)

5 Market Analysis by Type
    5.1 World Myotonic Dystrophy Therapeutics Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Sodium Channel Blocker
        5.2.2 Tricyclic Antidepressant
        5.2.3 Other
    5.3 Market Segment by Type
        5.3.1 World Myotonic Dystrophy Therapeutics Production by Type (2019-2030)
        5.3.2 World Myotonic Dystrophy Therapeutics Production Value by Type (2019-2030)
        5.3.3 World Myotonic Dystrophy Therapeutics Average Price by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Myotonic Dystrophy Therapeutics Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Hospital Pharmacy
        6.2.2 Retail Pharmacy
        6.2.3 Other
    6.3 Market Segment by Application
        6.3.1 World Myotonic Dystrophy Therapeutics Production by Application (2019-2030)
        6.3.2 World Myotonic Dystrophy Therapeutics Production Value by Application (2019-2030)
        6.3.3 World Myotonic Dystrophy Therapeutics Average Price by Application (2019-2030)

7 Company Profiles
    7.1 Lupin
        7.1.1 Lupin Details
        7.1.2 Lupin Major Business
        7.1.3 Lupin Myotonic Dystrophy Therapeutics Product and Services
        7.1.4 Lupin Myotonic Dystrophy Therapeutics Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.1.5 Lupin Recent Developments/Updates
        7.1.6 Lupin Competitive Strengths & Weaknesses
    7.2 Teva
        7.2.1 Teva Details
        7.2.2 Teva Major Business
        7.2.3 Teva Myotonic Dystrophy Therapeutics Product and Services
        7.2.4 Teva Myotonic Dystrophy Therapeutics Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.2.5 Teva Recent Developments/Updates
        7.2.6 Teva Competitive Strengths & Weaknesses
    7.3 ANI Pharmaceuticals
        7.3.1 ANI Pharmaceuticals Details
        7.3.2 ANI Pharmaceuticals Major Business
        7.3.3 ANI Pharmaceuticals Myotonic Dystrophy Therapeutics Product and Services
        7.3.4 ANI Pharmaceuticals Myotonic Dystrophy Therapeutics Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.3.5 ANI Pharmaceuticals Recent Developments/Updates
        7.3.6 ANI Pharmaceuticals Competitive Strengths & Weaknesses
    7.4 Viatris
        7.4.1 Viatris Details
        7.4.2 Viatris Major Business
        7.4.3 Viatris Myotonic Dystrophy Therapeutics Product and Services
        7.4.4 Viatris Myotonic Dystrophy Therapeutics Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.4.5 Viatris Recent Developments/Updates
        7.4.6 Viatris Competitive Strengths & Weaknesses
    7.5 Novartis
        7.5.1 Novartis Details
        7.5.2 Novartis Major Business
        7.5.3 Novartis Myotonic Dystrophy Therapeutics Product and Services
        7.5.4 Novartis Myotonic Dystrophy Therapeutics Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.5.5 Novartis Recent Developments/Updates
        7.5.6 Novartis Competitive Strengths & Weaknesses
    7.6 Sun Pharma
        7.6.1 Sun Pharma Details
        7.6.2 Sun Pharma Major Business
        7.6.3 Sun Pharma Myotonic Dystrophy Therapeutics Product and Services
        7.6.4 Sun Pharma Myotonic Dystrophy Therapeutics Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.6.5 Sun Pharma Recent Developments/Updates
        7.6.6 Sun Pharma Competitive Strengths & Weaknesses
    7.7 Mallinckrodt
        7.7.1 Mallinckrodt Details
        7.7.2 Mallinckrodt Major Business
        7.7.3 Mallinckrodt Myotonic Dystrophy Therapeutics Product and Services
        7.7.4 Mallinckrodt Myotonic Dystrophy Therapeutics Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.7.5 Mallinckrodt Recent Developments/Updates
        7.7.6 Mallinckrodt Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Myotonic Dystrophy Therapeutics Industry Chain
    8.2 Myotonic Dystrophy Therapeutics Upstream Analysis
        8.2.1 Myotonic Dystrophy Therapeutics Core Raw Materials
        8.2.2 Main Manufacturers of Myotonic Dystrophy Therapeutics Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Myotonic Dystrophy Therapeutics Production Mode
    8.6 Myotonic Dystrophy Therapeutics Procurement Model
    8.7 Myotonic Dystrophy Therapeutics Industry Sales Model and Sales Channels
        8.7.1 Myotonic Dystrophy Therapeutics Sales Model
        8.7.2 Myotonic Dystrophy Therapeutics Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Myotonic Dystrophy Therapeutics Production Value by Region (2019, 2023 and 2030) & (USD Million)
    Table 2. World Myotonic Dystrophy Therapeutics Production Value by Region (2019-2024) & (USD Million)
    Table 3. World Myotonic Dystrophy Therapeutics Production Value by Region (2025-2030) & (USD Million)
    Table 4. World Myotonic Dystrophy Therapeutics Production Value Market Share by Region (2019-2024)
    Table 5. World Myotonic Dystrophy Therapeutics Production Value Market Share by Region (2025-2030)
    Table 6. World Myotonic Dystrophy Therapeutics Production by Region (2019-2024) & (K Units)
    Table 7. World Myotonic Dystrophy Therapeutics Production by Region (2025-2030) & (K Units)
    Table 8. World Myotonic Dystrophy Therapeutics Production Market Share by Region (2019-2024)
    Table 9. World Myotonic Dystrophy Therapeutics Production Market Share by Region (2025-2030)
    Table 10. World Myotonic Dystrophy Therapeutics Average Price by Region (2019-2024) & (US$/Unit)
    Table 11. World Myotonic Dystrophy Therapeutics Average Price by Region (2025-2030) & (US$/Unit)
    Table 12. Myotonic Dystrophy Therapeutics Major Market Trends
    Table 13. World Myotonic Dystrophy Therapeutics Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
    Table 14. World Myotonic Dystrophy Therapeutics Consumption by Region (2019-2024) & (K Units)
    Table 15. World Myotonic Dystrophy Therapeutics Consumption Forecast by Region (2025-2030) & (K Units)
    Table 16. World Myotonic Dystrophy Therapeutics Production Value by Manufacturer (2019-2024) & (USD Million)
    Table 17. Production Value Market Share of Key Myotonic Dystrophy Therapeutics Producers in 2023
    Table 18. World Myotonic Dystrophy Therapeutics Production by Manufacturer (2019-2024) & (K Units)
    Table 19. Production Market Share of Key Myotonic Dystrophy Therapeutics Producers in 2023
    Table 20. World Myotonic Dystrophy Therapeutics Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 21. Global Myotonic Dystrophy Therapeutics Company Evaluation Quadrant
    Table 22. World Myotonic Dystrophy Therapeutics Industry Rank of Major Manufacturers, Based on Production Value in 2023
    Table 23. Head Office and Myotonic Dystrophy Therapeutics Production Site of Key Manufacturer
    Table 24. Myotonic Dystrophy Therapeutics Market: Company Product Type Footprint
    Table 25. Myotonic Dystrophy Therapeutics Market: Company Product Application Footprint
    Table 26. Myotonic Dystrophy Therapeutics Competitive Factors
    Table 27. Myotonic Dystrophy Therapeutics New Entrant and Capacity Expansion Plans
    Table 28. Myotonic Dystrophy Therapeutics Mergers & Acquisitions Activity
    Table 29. United States VS China Myotonic Dystrophy Therapeutics Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 30. United States VS China Myotonic Dystrophy Therapeutics Production Comparison, (2019 & 2023 & 2030) & (K Units)
    Table 31. United States VS China Myotonic Dystrophy Therapeutics Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
    Table 32. United States Based Myotonic Dystrophy Therapeutics Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Myotonic Dystrophy Therapeutics Production Value, (2019-2024) & (USD Million)
    Table 34. United States Based Manufacturers Myotonic Dystrophy Therapeutics Production Value Market Share (2019-2024)
    Table 35. United States Based Manufacturers Myotonic Dystrophy Therapeutics Production (2019-2024) & (K Units)
    Table 36. United States Based Manufacturers Myotonic Dystrophy Therapeutics Production Market Share (2019-2024)
    Table 37. China Based Myotonic Dystrophy Therapeutics Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Myotonic Dystrophy Therapeutics Production Value, (2019-2024) & (USD Million)
    Table 39. China Based Manufacturers Myotonic Dystrophy Therapeutics Production Value Market Share (2019-2024)
    Table 40. China Based Manufacturers Myotonic Dystrophy Therapeutics Production (2019-2024) & (K Units)
    Table 41. China Based Manufacturers Myotonic Dystrophy Therapeutics Production Market Share (2019-2024)
    Table 42. Rest of World Based Myotonic Dystrophy Therapeutics Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Myotonic Dystrophy Therapeutics Production Value, (2019-2024) & (USD Million)
    Table 44. Rest of World Based Manufacturers Myotonic Dystrophy Therapeutics Production Value Market Share (2019-2024)
    Table 45. Rest of World Based Manufacturers Myotonic Dystrophy Therapeutics Production (2019-2024) & (K Units)
    Table 46. Rest of World Based Manufacturers Myotonic Dystrophy Therapeutics Production Market Share (2019-2024)
    Table 47. World Myotonic Dystrophy Therapeutics Production Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 48. World Myotonic Dystrophy Therapeutics Production by Type (2019-2024) & (K Units)
    Table 49. World Myotonic Dystrophy Therapeutics Production by Type (2025-2030) & (K Units)
    Table 50. World Myotonic Dystrophy Therapeutics Production Value by Type (2019-2024) & (USD Million)
    Table 51. World Myotonic Dystrophy Therapeutics Production Value by Type (2025-2030) & (USD Million)
    Table 52. World Myotonic Dystrophy Therapeutics Average Price by Type (2019-2024) & (US$/Unit)
    Table 53. World Myotonic Dystrophy Therapeutics Average Price by Type (2025-2030) & (US$/Unit)
    Table 54. World Myotonic Dystrophy Therapeutics Production Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 55. World Myotonic Dystrophy Therapeutics Production by Application (2019-2024) & (K Units)
    Table 56. World Myotonic Dystrophy Therapeutics Production by Application (2025-2030) & (K Units)
    Table 57. World Myotonic Dystrophy Therapeutics Production Value by Application (2019-2024) & (USD Million)
    Table 58. World Myotonic Dystrophy Therapeutics Production Value by Application (2025-2030) & (USD Million)
    Table 59. World Myotonic Dystrophy Therapeutics Average Price by Application (2019-2024) & (US$/Unit)
    Table 60. World Myotonic Dystrophy Therapeutics Average Price by Application (2025-2030) & (US$/Unit)
    Table 61. Lupin Basic Information, Manufacturing Base and Competitors
    Table 62. Lupin Major Business
    Table 63. Lupin Myotonic Dystrophy Therapeutics Product and Services
    Table 64. Lupin Myotonic Dystrophy Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 65. Lupin Recent Developments/Updates
    Table 66. Lupin Competitive Strengths & Weaknesses
    Table 67. Teva Basic Information, Manufacturing Base and Competitors
    Table 68. Teva Major Business
    Table 69. Teva Myotonic Dystrophy Therapeutics Product and Services
    Table 70. Teva Myotonic Dystrophy Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 71. Teva Recent Developments/Updates
    Table 72. Teva Competitive Strengths & Weaknesses
    Table 73. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 74. ANI Pharmaceuticals Major Business
    Table 75. ANI Pharmaceuticals Myotonic Dystrophy Therapeutics Product and Services
    Table 76. ANI Pharmaceuticals Myotonic Dystrophy Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 77. ANI Pharmaceuticals Recent Developments/Updates
    Table 78. ANI Pharmaceuticals Competitive Strengths & Weaknesses
    Table 79. Viatris Basic Information, Manufacturing Base and Competitors
    Table 80. Viatris Major Business
    Table 81. Viatris Myotonic Dystrophy Therapeutics Product and Services
    Table 82. Viatris Myotonic Dystrophy Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 83. Viatris Recent Developments/Updates
    Table 84. Viatris Competitive Strengths & Weaknesses
    Table 85. Novartis Basic Information, Manufacturing Base and Competitors
    Table 86. Novartis Major Business
    Table 87. Novartis Myotonic Dystrophy Therapeutics Product and Services
    Table 88. Novartis Myotonic Dystrophy Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 89. Novartis Recent Developments/Updates
    Table 90. Novartis Competitive Strengths & Weaknesses
    Table 91. Sun Pharma Basic Information, Manufacturing Base and Competitors
    Table 92. Sun Pharma Major Business
    Table 93. Sun Pharma Myotonic Dystrophy Therapeutics Product and Services
    Table 94. Sun Pharma Myotonic Dystrophy Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 95. Sun Pharma Recent Developments/Updates
    Table 96. Mallinckrodt Basic Information, Manufacturing Base and Competitors
    Table 97. Mallinckrodt Major Business
    Table 98. Mallinckrodt Myotonic Dystrophy Therapeutics Product and Services
    Table 99. Mallinckrodt Myotonic Dystrophy Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 100. Global Key Players of Myotonic Dystrophy Therapeutics Upstream (Raw Materials)
    Table 101. Myotonic Dystrophy Therapeutics Typical Customers
    Table 102. Myotonic Dystrophy Therapeutics Typical Distributors
List of Figure
    Figure 1. Myotonic Dystrophy Therapeutics Picture
    Figure 2. World Myotonic Dystrophy Therapeutics Production Value: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Myotonic Dystrophy Therapeutics Production Value and Forecast (2019-2030) & (USD Million)
    Figure 4. World Myotonic Dystrophy Therapeutics Production (2019-2030) & (K Units)
    Figure 5. World Myotonic Dystrophy Therapeutics Average Price (2019-2030) & (US$/Unit)
    Figure 6. World Myotonic Dystrophy Therapeutics Production Value Market Share by Region (2019-2030)
    Figure 7. World Myotonic Dystrophy Therapeutics Production Market Share by Region (2019-2030)
    Figure 8. North America Myotonic Dystrophy Therapeutics Production (2019-2030) & (K Units)
    Figure 9. Europe Myotonic Dystrophy Therapeutics Production (2019-2030) & (K Units)
    Figure 10. China Myotonic Dystrophy Therapeutics Production (2019-2030) & (K Units)
    Figure 11. Japan Myotonic Dystrophy Therapeutics Production (2019-2030) & (K Units)
    Figure 12. Myotonic Dystrophy Therapeutics Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Myotonic Dystrophy Therapeutics Consumption (2019-2030) & (K Units)
    Figure 15. World Myotonic Dystrophy Therapeutics Consumption Market Share by Region (2019-2030)
    Figure 16. United States Myotonic Dystrophy Therapeutics Consumption (2019-2030) & (K Units)
    Figure 17. China Myotonic Dystrophy Therapeutics Consumption (2019-2030) & (K Units)
    Figure 18. Europe Myotonic Dystrophy Therapeutics Consumption (2019-2030) & (K Units)
    Figure 19. Japan Myotonic Dystrophy Therapeutics Consumption (2019-2030) & (K Units)
    Figure 20. South Korea Myotonic Dystrophy Therapeutics Consumption (2019-2030) & (K Units)
    Figure 21. ASEAN Myotonic Dystrophy Therapeutics Consumption (2019-2030) & (K Units)
    Figure 22. India Myotonic Dystrophy Therapeutics Consumption (2019-2030) & (K Units)
    Figure 23. Producer Shipments of Myotonic Dystrophy Therapeutics by Manufacturer Revenue ($MM) and Market Share (%): 2023
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Myotonic Dystrophy Therapeutics Markets in 2023
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Myotonic Dystrophy Therapeutics Markets in 2023
    Figure 26. United States VS China: Myotonic Dystrophy Therapeutics Production Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 27. United States VS China: Myotonic Dystrophy Therapeutics Production Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Myotonic Dystrophy Therapeutics Consumption Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. United States Based Manufacturers Myotonic Dystrophy Therapeutics Production Market Share 2023
    Figure 30. China Based Manufacturers Myotonic Dystrophy Therapeutics Production Market Share 2023
    Figure 31. Rest of World Based Manufacturers Myotonic Dystrophy Therapeutics Production Market Share 2023
    Figure 32. World Myotonic Dystrophy Therapeutics Production Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 33. World Myotonic Dystrophy Therapeutics Production Value Market Share by Type in 2023
    Figure 34. Sodium Channel Blocker
    Figure 35. Tricyclic Antidepressant
    Figure 36. Other
    Figure 37. World Myotonic Dystrophy Therapeutics Production Market Share by Type (2019-2030)
    Figure 38. World Myotonic Dystrophy Therapeutics Production Value Market Share by Type (2019-2030)
    Figure 39. World Myotonic Dystrophy Therapeutics Average Price by Type (2019-2030) & (US$/Unit)
    Figure 40. World Myotonic Dystrophy Therapeutics Production Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 41. World Myotonic Dystrophy Therapeutics Production Value Market Share by Application in 2023
    Figure 42. Hospital Pharmacy
    Figure 43. Retail Pharmacy
    Figure 44. Other
    Figure 45. World Myotonic Dystrophy Therapeutics Production Market Share by Application (2019-2030)
    Figure 46. World Myotonic Dystrophy Therapeutics Production Value Market Share by Application (2019-2030)
    Figure 47. World Myotonic Dystrophy Therapeutics Average Price by Application (2019-2030) & (US$/Unit)
    Figure 48. Myotonic Dystrophy Therapeutics Industry Chain
    Figure 49. Myotonic Dystrophy Therapeutics Procurement Model
    Figure 50. Myotonic Dystrophy Therapeutics Sales Model
    Figure 51. Myotonic Dystrophy Therapeutics Sales Channels, Direct Sales, and Distribution
    Figure 52. Methodology
    Figure 53. Research Process and Data Source

Companies Mentioned

Lupin
Teva
ANI Pharmaceuticals
Viatris
Novartis
Sun Pharma
Mallinckrodt